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Colchlcine, an anthmitogenic agent, has shown promise in 
the prevention of restenosis after car 
(PTCA) in experimental animal models. e randomized 197 
pts 2:l to colchicine 0.6 mg po bid (1 
(67 pts) for 6 months following elective PTCA. Treatment 
was begun within 24 hours of PTCA. 96X of all prescribed 
pills were ingested. The mean age of the study population 
was 60 years; 169 pts ($6 ) were men. Demographic 
characteristics were similar in the two groups. A mean of 
2.7 lesions were dilated per t. Side-effects (diarrhea, 
drop-out rate in colchicine 
giographic follow-up was 
antitative measurements were 
s on the 393 lesions dilated 
in the 145 pts with baseline (pre-PTCA) immediate post- 
PTCA (post-PTCA) and 6 months follow-up (6 mos) angio- 
graphic films 
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The lesion restenosi e (defined as a return to 
stenosis and loss of of the initial gain) was 
placebo pts and 22% lchicine pts (p+iS). The patient 
rates were also not different in the 2 groups 
* Colchicine is ineffective for the prevention 
of restenok after PTCA. 
We hypothesized that long-term adminjstration t$ heparin may 
meas ary ang$.rasty by its favorable 
ects muscle proliferation, and lipid 
metabol rolled trial was therefore initiated, 
with pat ive either 10,000 units subcutan- 
eous heparin daily, or usual care. Of the 23 patients who compr@ted 
the protocol at the time of study te nation, 14 out of 17 receiving 
heparin experienced restenosis ocumented by quantitative 
angiographic analysis (62% ws 33% for controls, peO.05). 
Restenosis also appeared higher en examined on a per-lesion 
basis (60% vs 22%, p=O.O6). an lclss of initial diameter 
improvement was 53 f 16% [S vs -20 f 46% for controls. 
Secondary endpoints were also higher in the heparin group, with 13 
patients with recurrent angina (76% v,c t 7%) 3 with % ws O%), 
and 1 with cardiac death (6% vs 0%). ~om~li~tions associated with 
the study were limited to the heparin group, with 7 patients 
experiencing abnormal bleeding 1% ws O%), leading to surgery in 
1 individual. The study was terminated prior to achievement of 
targeted enrollment on ethical grounds. 
Thus, chronic heparin use after successful coronary angioplasty 
paradoxically appears to increase the likelihood of 
restenosis and adverse clinical outcome. 
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pectlvely. Intimal 
as area of intimal 
nisms kdtiate 
grgups were similar with respect to age (61 +I 3.5 vs 60t12.5, 
~~0.05 and other demographic characteristics. Restenosis, 
define cl as the presentation to ‘an with s mptoms of 
anaina within 6 months of the d the fin J ing on repeat 
